Bicycle Therapeutics (BCYC) AI Stock Analysis

• Market Cap: $476.14M
• Dividend Yield: N/A
• Average Volume (3M): 337.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: -23.43%
• EPS Growth: -9.84%
• Country: US
• Employees: 305
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 49,929,950
• 10 Day Avg. Volume: 299,285
• 30 Day Avg. Volume: 337,652
• PEG Ratio: 0.11
• Price to Book (P/B): 1.03
• Price to Sales (P/S): 23.10
• P/FCF Ratio: -4.91
• Enterprise Value/Market Cap: -0.22
• Enterprise Value/Revenue: -3.72
• Enterprise Value/Gross Profit: 0.68
• Enterprise Value/Ebitda: 0.39
• 1Y Price Target: $20.75
• Price Target Upside: 202.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -3.86
• Revenue Forecast (FY): $32.45M

• Rating: 41 Neutral
• Price Target: $7.00 ▲(1.89% Upside)

Bicycle Therapeutics faces significant financial challenges, with negative profitability and cash flow issues being the most critical factors. The technical analysis suggests potential short-term overbought conditions, but the overall trend is bearish. Valuation remains unattractive due to ongoing losses. The company's focus should be on improving operational efficiency and profitability to enhance its financial health.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, which can drive long-term business expansion and sustainability.

Low Leverage

Minimal leverage enhances financial stability and flexibility, allowing the company to invest in growth opportunities without significant debt burden.

Proprietary Platform

The proprietary platform offers a competitive advantage in drug development, potentially leading to breakthrough treatments and long-term market leadership.

Negative Factors

Negative Profit Margins

Negative profit margins indicate high operational costs relative to revenue, which can hinder profitability and long-term financial health.

Negative Operating Cash Flow

Negative operating cash flow suggests difficulties in sustaining operations without external financing, impacting long-term viability and growth.

Negative Return on Equity

Negative ROE indicates poor efficiency in using equity capital to generate profits, potentially deterring future investment and growth.

Bicycle Therapeutics Business Overview & Revenue Model

Company Description

Bicycle Therapeutics (BCYC) is a biotechnology company focused on developing a new class of medicines known as bicyclic peptide therapeutics. Leveraging its proprietary bicyclic peptide platform, the company aims to create innovative treatments primarily in the fields of oncology and other serious diseases. Bicycle Therapeutics is dedicated to addressing unmet medical needs by harnessing the unique properties of bicyclic peptides, which offer advantages such as enhanced stability, solubility, and targeted delivery compared to traditional therapeutic modalities.

How the Company Makes Money

Bicycle Therapeutics generates revenue through a combination of partnerships, collaborations, and licensing agreements with pharmaceutical companies for the development and commercialization of its therapeutics. The company may receive upfront payments, milestone payments based on the achievement of specific development or regulatory milestones, and royalties on future sales of approved products. Additionally, BCYC may engage in research collaborations that provide funding and support for its drug development programs, further contributing to its revenue stream.

Bicycle Therapeutics Financial Statement Overview

Summary

Bicycle Therapeutics is experiencing robust revenue growth but faces significant profitability challenges with negative margins. The balance sheet is stable with low leverage, but the company struggles to generate positive returns on equity. Cash flow management remains a concern, with negative operating cash flow despite positive free cash flow relative to net income.

Income Statement

Bicycle Therapeutics has shown a significant revenue growth rate of 46.98% in the TTM, indicating strong top-line expansion. However, the company is struggling with negative margins across the board, including a gross profit margin of -5.92% and a net profit margin of -8.85%, reflecting ongoing operational challenges and high costs relative to revenue.

Balance Sheet

The company's balance sheet shows a very low debt-to-equity ratio of 0.0016, indicating minimal leverage, which is a positive sign of financial stability. However, the return on equity is negative at -35.54%, highlighting inefficiencies in generating returns from shareholder investments. The equity ratio stands at a healthy level, suggesting a strong capital structure.

Cash Flow

Bicycle Therapeutics has a positive free cash flow to net income ratio of 1.01, indicating that it is generating free cash flow relative to its net losses. However, the operating cash flow is negative, and the company is experiencing challenges in covering its operational expenses, as reflected by the negative operating cash flow coverage ratio.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.34M	35.27M	26.98M	14.46M	11.70M	10.39M
Gross Profit	-156.03M	-137.69M	-129.52M	14.46M	11.70M	-22.76M
EBITDA	-270.69M	-164.89M	-183.40M	-107.21M	-64.09M	-50.68M
Net Income	-250.66M	-169.03M	-180.66M	-112.72M	-66.82M	-51.01M
Balance Sheet
Total Assets	763.95M	956.87M	595.34M	410.61M	479.79M	161.15M
Cash, Cash Equivalents and Short-Term Investments	648.33M	879.52M	526.42M	339.15M	438.68M	135.99M
Total Debt	5.74M	9.49M	44.96M	44.33M	44.34M	15.78M
Total Liabilities	145.47M	163.81M	224.41M	139.83M	133.54M	65.69M
Stockholders Equity	618.48M	793.06M	370.93M	270.78M	346.25M	95.46M
Cash Flow
Free Cash Flow	-242.20M	-165.96M	-63.56M	-105.10M	-16.82M	-18.99M
Operating Cash Flow	-240.02M	-164.72M	-60.63M	-86.11M	-14.79M	-17.79M
Investing Cash Flow	-2.15M	-1.24M	-2.93M	-18.99M	-2.03M	-1.20M
Financing Cash Flow	86.84K	519.75M	250.03M	6.69M	320.73M	62.84M

Bicycle Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCYC, the sentiment is Neutral. The current price of 6.87 is above the 20-day moving average (MA) of 6.66, below the 50-day MA of 7.50, and below the 200-day MA of 8.04, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 51.77 is Neutral, neither overbought nor oversold. The STOCH value of 54.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BCYC.

Bicycle Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETON	56 Neutral	$414.33M	―	-34.17%	―	102.77%	-17.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCAX	48 Neutral	$939.51M	―	-26.64%	―	―	―
NBTX	48 Neutral	$979.39M	―	―	―	―	―
BCYC	41 Neutral	$476.14M	―	-34.63%	―	-23.43%	-9.84%
OPT	39 Underperform	$477.76M	-3.01	―	―	-80.09%	60.14%
KOD	35 Underperform	$1.17B	-5.57	-207.92%	―	―	-12.93%

Bicycle Therapeutics Corporate Events

Bicycle Therapeutics Reports Q3 2025 Financial Results

Bicycle Therapeutics is a clinical-stage pharmaceutical company based in the United Kingdom, specializing in the development of a novel class of medicines known as Bicycle molecules, primarily targeting oncology indications with high unmet medical needs. The company is known for its unique therapeutic modality that combines the pharmacology of biologics with the manufacturing and pharmacokinetic properties of small molecules.

Bicycle Therapeutics Expands Board with New Appointments

On September 8, 2025, Bicycle Therapeutics announced the expansion of its Board of Directors from eight to ten members, appointing Roger Dansey, M.D., and Hervé Hoppenot as new directors. Both appointees bring extensive expertise in oncology research, drug development, and commercialization, which is expected to enhance the company’s strategic initiatives in developing next-generation targeted therapies. The appointments are seen as a strategic move to strengthen the company’s leadership as it progresses with its pipeline and anticipates upcoming milestones.

The most recent analyst rating on (BCYC) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.